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ABSTRACT 
 
Background: Research on vasopressin (AVP) in cirrhosis and its role in the assessment 
of prognosis has been hindered by the difficulty of measuring AVP levels accurately. 
Copeptin, a 39-aminoacid glycopeptide, is released from the neurohypophysis together 
with AVP. Copeptin could have a role as biomarker of prognosis in cirrhosis as it may 
reflect circulatory dysfunction. The aim of this study is to investigate the role of 
copeptin as biomarker of disease progression and prognosis in cirrhosis. 
Methods: This prospective study is divided in 2 study protocols including 321 
consecutive patients. Plasma copeptin levels were measured in all patients at study 
inclusion. Protocol 1: to investigate the relationship of copeptin with kidney and 
circulatory function (56 patients). Protocol 2: to investigate the relationship between 
copeptin and prognosis, as assessed by the development of complications of cirrhosis 
or mortality at 3 months (265 patients admitted to hospital for complications of 
cirrhosis). 
Results: Patients with decompensated cirrhosis showed significantly higher plasma 
copeptin levels compared to those of patients with compensated cirrhosis. Copeptin 
levels had a significant positive correlation with model for end-satge liver disease 
(MELD) score, AVP, endogenous vasoconstrictor systems, and kidney function 
parameters. Patients developing complications of cirrhosis or mortality had 
significantly higher plasma copeptin levels compared to those of the remaining 
patients. Plasma copeptin levels were an independent predictive factor of both the 
development of complications and mortality at 3 months. This was confirmed in a 
validation series of 120 patients. 
Conclusions: Copeptin is a novel biomarker of disease progression 
and prognosis in cirrhosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Natural history of cirrhosis is characterized by decompensation of the disease, which is 
associated with high morbidity and mortality.1 Clinical decompensation is mainly 
related to a progressive increase in portal hypertension and circulatory dysfunction. In 
the early stages of the disease when cirrhosis is compensated and patients are still 
asymptomatic, there is only a slight decrease in systemic vascular resistance and 
arterial effective blood volume and blood pressure are maintained within normal 
levels.2,3 As disease progresses, patients develop clinical decompensation associated 
with worsening circulatory dysfunction. In this stage of the disease, circulatory 
dysfunction is characterized by marked decrease in systemic vascular resistance due to 
an intense splanchnic vasodilation that leads to a reduction in effective arterial blood 
volume. In order to maintain arterial pressure within normal limits there is a marked 
activation of endogenous vasoconstrictor systems, such as renin-angiotensin-
aldosterone system, and sympathetic nervous system. In more advanced stages of the 
disease, there is non-osmotic secretion of vasopressin (AVP). The activation of these 
vasoconstrictor systems helps improve circulatory function but has negative effects on 
kidney function leading to renal sodium and solute-free water retention, which is 
associated with development of ascites and dilutional hyponatremia. Eventually, there 
is an intense kidney vasoconstriction leading to hepatorenal syndrome.2,3 Therefore, 
considering the pathophysiology of disease progression, AVP could theoretically 
represent a biomarker of advanced disease, clinical decompensation and prognosis in 
cirrhosis. However, research on AVP in cirrhosis and its role in the pathophysiology of 
the disease has been hindered by the difficulty of measuring AVP levels accurately. The 
accurate measurement of plasma AVP levels is difficult because of its short half-life 
and methodological issues.4-6 
 
Copeptin, a 39-aminoacid glycopeptide, is released from the neurohypophysis 
stoichiometrically with AVP, within the precursor preprovasopressin.7-9 The precursor 
consists of a signal peptide, AVP, neurophysin-II, and copeptin. In contrast to AVP, 
copeptin is a non-functional peptide which is very stable and easier to measure.7-9 
There is evidence suggesting that copeptin is a good surrogate marker of AVP, as there 
is a good correlation between AVP and copeptin levels.10-13 The development of a 
reliable immunoassay to measure copeptin allows investigation into the role of AVP as 
a biomarker in clinical practice.10 Moreover, assessment of plasma copeptin levels may 
help understand the mechanism(s) of the increased release of AVP from the 
neurohypophysis into the circulation and its pathogenic role in cirrhosis. 
 
Copeptin has been shown to be associated with prognosis in several diseases such as 
heart failure, chronic respiratory diseases and critically-ill patients.14-20 However, 
information in cirrhosis is scarce.21 Therefore, the aim of our study was to assess the 
role of copeptin as biomarker of circulatory derangement, disease progression and 
acute decompensation in patients with cirrhosis. Moreover, the study was aimed at 
evaluating the usefulness of copeptin as a biomarker to predict prognosis in patients 
with cirrhosis including the validation of the prediction model in an independent 
cohort of patients. 
 
PATIENTS AND METHODS 
 
Study design 
 
This was a prospective study that included 321 consecutive patients with cirrhosis seen 
at the Liver Unit of Hospital Clinic of Barcelona from February 2011 to February 2013. 
The study was divided in two different protocols that were conducted simultaneously. 
Patients seen at the outpatient clinic were considered for protocol 1 and patients 
admitted to hospital for complications of cirrhosis were included in protocol 2. The 
only patients excluded from the study were: (1) patients with chronic kidney disease 
treated with hemodialysis before admission, (2) patients with previous liver or kidney 
transplantation, (3) patients with hepatocellular carcinoma beyond Milan criteria, (4) 
patients with advanced chronic respiratory or heart disease and (5) patients with 
severe extrahepatic diseases with poor short-term prognosis. All patients signed a 
written informed consent document and gave permission for samples to be used in the 
study following current national and institutional guidelines for sample storage and 
usage for research purposes. The study was approved by the Institutional Review 
Board of our center. 
 
 
Study protocol 1 
 
Fifty-six patients seen at the liver clinic were included, 18 (32%) with compensated 
cirrhosis and 38 (68%) with decompensated cirrhosis. The specific aim of this first part 
of the study was to investigate the relationship between plasma copeptin levels and 
kidney and circulatory function and the stages of the disease. 
 
Demographical, clinical and analytical data were collected from all patients at study 
inclusion. Analytical data for standard liver and kidney function tests and hematology 
were obtained from blood tests taken as part of usual clinical assistance. In addition, 
20 ml of blood were obtained to measure plasma levels of copeptin and endogenous 
vasoconstrictor systems: plasma renin activity (PRA) and the plasma concentrations of 
vasopressin, aldosterone, and noradrenaline. 
 
 
Study protocol 2 
 
Two-hundred and sixty-five consecutive patients admitted to hospital for 
complications of cirrhosis were prospectively included in the study. The specific aim of 
this part of the study was to assess the relationship between plasma copeptin levels 
and complications of cirrhosis and survival. 
 
Demographical, clinical and analytical data were collected from all patients at study 
inclusion. Analytical data for standard liver and kidney function tests and hematology 
were obtained from blood tests taken for usual clinical assistance. In addition, 10 ml of 
blood were obtained to measure plasma levels of copeptin. Patients were followed up 
for a 3-month period and complications of cirrhosis occurring both during 
hospitalization and after discharge from hospital were recorded. Complications were 
categorized as ascites, hepatic encephalopathy (HE), bacterial infections, 
gastrointestinal (GI) bleeding, hyponatremia, and kidney failure. 
 
 
Definitions 
 
Ascites was defined as the development of de novo ascites requiring initiation of 
diuretic treatment or worsening of previous existent ascites requiring an increase in 
diuretic treatment dose or large-volume paracentesis. Hepatic encephalopathy was 
defined as the development of grade ≥2 HE that required hospital admission. 
gastrointestinal bleeding was defined as portal hypertension related bleeding requiring 
hospital admission. Hyponatremia was defined as a decrease in serum sodium levels of 
5 mEq/L with respect to baseline with a final value <130 mEq/L. Kidney failure was 
defined as an increase of serum creatinine >50% with respect to baseline with a final 
value >1.5 mg/dl.22,23 Finally, bacterial infections were defined as reported in detail 
elsewhere.24 
 
 
Analytical methods 
 
Blood samples for plasma copeptin levels were processed within 2 h after blood 
extraction. Samples were centrifuged at 3000 g for 15 min at 4 °C and the supernatant 
stored at −80 °C until analysis. Copeptin was measured using a sandwich 
immunoluminometric assay using two polyclonal antibodies to the aminoacid 
sequences 132-147 and 149-164 in the C-terminal region of the vasopressin precursor 
(BRAHMS Copeptin US KRYPTOR, Thermofisher Scientific, Hennigsdorf, Germany). The 
assay is very sensitive, with an analytical detection limit of 1.7 pmol/L. Moreover, it has 
a good precision with an interlaboratory coefficient of variation (CV) <20% for all 
copeptin concentrations.10 
 
Measurement of plasma levels of vasopressin, PRA, aldosterone and noradrenaline 
was performed using previously described methods.25,26 Briefly, 10 ml of blood were 
obtained from patients after a 6 h fasting period and after maintenance of supine 
position for 1 h before blood sampling. All vasoactive hormones were analyzed using 
radioimmunoassay (Bühlmann, IBL International and Diiasorin, respectively) with intra-
assay coefficient of variation <7% and interassay coefficient of variation <15% for all 
the assays. 
 
 
Statistical analysis 
 
Results for continuous variables are expressed as mean ± standard deviation or median 
(interquartile range). Categorical variables are expressed as number and percentage. 
Comparisons between groups were made with standard statistical tests. Complications 
and survival probability curves were calculated with the Kaplan-Meier method and 
compared with Log-rank test. When analyzing three-month mortality, both mortality 
and liver transplantation were considered as an event. To assess the variables 
independently associated with complications of cirrhosis or 3-month mortality, a 
logistic regression model was performed. The model was fitted applying a forward 
stepwise selection method with p in=0.05 and p out=0.1. In order to avoid collinearity 
with Child-Pugh and MELD scores, individual variables included in these scores were 
not included in the model. An internal validation of the prediction model of mortality 
was performed with the use of the bootstrapping technique. Moreover, the 
performance of the model was evaluated in an external validation with an 
independent series including patients from other centers. Variables with skewed 
distribution, such as copeptin, were log-transformed before being included in the 
analysis. Since the number of missing data was very low, particularly for the main 
variables, no imputation of missing data was used and a complete cases analysis was 
performed. All statistical analyses were performed using SPSS 20.0 software. The 
significance level for all statistical tests was set at 0.05 two-tailed. The results of the 
study are reported following the TRIPOD (transparent reporting of a multivariable 
prediction model for individual prognosis or diagnosis) Statement recommendations.27 
 
 
 
RESULTS 
 
 
Study protocol 1 
 
Characteristics of the patient population 
 
Out of the 56 patients included in this first part of the study, 64% were male and the 
main etiology of cirrhosis was alcohol (54%). Patients had a moderate impairment in 
liver function as reflected by slightly increased serum bilirubin levels (3.3 ± 5 mg/dl) 
and a mean MELD score of 11. Baseline demographical, clinical and analytical data of 
this series of patients are shown in Supplementary table 1. 
 
 
Plasma copeptin levels and relationship with liver, kidney and circulatory function 
 
In the overall series, median plasma copeptin levels were 12 pmol/L (IQR 5–26). 
Plasma copeptin levels were not related to age, gender, etiology of cirrhosis or the 
presence of active alcoholism at the time of inclusion. Plasma copeptin levels were 
markedly higher in patients with decompensated cirrhosis compared to those in 
patients with compensated cirrhosis [median 21 (IQR 8.1–49.5) vs. 4.5 (2.9–8.4) 
pmol/L, respectively; p<0.0001, figure 1A]. Moreover, when patients were stratified 
according to Child-Pugh class, plasma copeptin levels were significantly higher in 
patients with Child-Pugh class B [10.7 (6.4–24.1) pmol/L] and C [59.9 (19.3–75.7) 
pmol/L] compared to patients with Child-Pugh A [4.6 pmol/L (3.1–12.4)], p=0.001. 
Similarly, when patients were categorized according to MELD score, plasma copeptin 
levels were significantly higher in patients with MELD score >10 (median value of the 
series), compared to patients with MELD score ≤10 [23 (9.7–60.2) vs. 6.5 (4.1–13.8), 
respectively; p<0.0001, figure 1B]. Indeed, there was a positive and significant 
correlation between copeptin and MELD score (r=0.677; p<0.0001). 
 
We then analyzed the relationship between plasma copeptin levels and kidney and 
circulatory function. There was a positive and statistically significant correlation 
between plasma copeptin levels and kidney function, as estimated by serum creatinine 
concentration (r=0.603, p<0.0001). Besides, copeptin was negatively correlated with 
mean arterial pressure (r=−0.399, p=0.003). Moreover, there was a significant positive 
correlation between plasma copeptin and endogenous vasoconstrictor systems as 
reflected by correlation with PRA (r=0.445, p=0.001), aldosterone (r=0.487, p<0.0001) 
and noradrenaline (r=0.459, p=0.001). 
 
Finally, as copeptin is the C-terminal fragment of AVP we also analyzed the relationship 
between plasma copeptin and vasopressin, serum sodium levels and plasma 
osmolality. In keeping with results from previous studies in other disease conditions, 
there was a significant and positive correlation between plasma copeptin and 
vasopressin levels (r=0.654; p<0.0001). Moreover there was a statistically significant 
inverse correlation with serum sodium levels (r=−0.462, p<0.0001); however, there 
was no significant correlation with plasma osmolality (r=−0.109; p=0.438). When 
patients were categorized according to baseline serum sodium levels, patients with 
hyponatremia had significantly higher plasma copeptin levels compared to those with 
normal serum sodium concentration [24.2 (7.7–64.3) vs. 10.9 (4.5–23) pmol/L, 
respectively, p=0.026]. 
 
 
Study protocol 2 
 
Characteristics of the patient population 
 
Demographical and clinical data, and liver and kidney function tests of the 265 patients 
included in this part of the study are shown in table 1. Patients had moderately-severe 
impairment of liver function as reflected by high serum bilirubin, mean MELD score of 
17 and Child-Pugh score of 9. Patients had a moderate impairment of kidney function 
with mean serum creatinine of 1.3 mg/dl. 
 
 
Plasma copeptin levels and clinical outcomes 
 
In this series of patients, median plasma copeptin levels were 14 pmol/L (IQR 7.3–33). 
Out of the 265 patients enrolled, 206 patients (78%) developed complications of 
cirrhosis either during hospitalization or after discharge from hospital. The most 
frequent complication was bacterial infections in 121 patients (46%), followed by HE 
(38%), kidney failure (33%), ascites (25%), hyponatremia (17%) and gastrointestinal 
bleeding (11%). Patients developing complications of cirrhosis during follow-up had 
significantly higher plasma copeptin levels compared to those patients patients who 
did not develop complications during follow-up [17 (9–38) vs. 8.6 (6–17) pmol/L, 
respectively; p<0.0001]. Patients developing any of the individual complications of 
cirrhosis, except for ascites and hyponatremia, had significantly higher plasma 
copeptin levels compared to those of patients who did not develop these 
complications (table 2). 
 
In univariate analysis, besides plasma copeptin levels, other variables significantly 
associated with development of complications of cirrhosis were: prior history of 
ascites, HE or infections, serum bilirubin, international normalized ratio (INR), serum 
creatinine, serum sodium, AVP levels, and MELD and Child-Pugh scores 
(supplementary table 2). Patients with plasma copeptin levels >14 pmol/L (median 
value of the whole series) had a probability of developing complications during follow-
up significantly higher than that of patients with plasma copeptin levels ≤14 pmol/L 
(78% vs. 60%, respectively; p= 0.005). A logistic regression model showed that plasma 
copeptin levels together with serum sodium were independent predictive factors of 
development of complications of cirrhosis during follow-up [Area under receiver 
operating characteristic (AUROC)=0.723; 95% CI (0.650–0.796), table 3]. 
 
Out of the 265 patients, 63 patients died (24%) and 16 were transplanted (6%) during 
the 3-month follow-up period. Patients who died during follow-up showed significantly 
higher plasma copeptin levels compared to those of patients who were alive at the end 
of follow-up [37.7 (12–63) vs. 11.8 (6–23), respectively; p<0.0001]. Figure 2 shows the 
probability of survival in all patients categorized according to the median value of 
plasma copeptin in the whole series. In univariate analysis, other variables associated 
with 3-month mortality were: previous ascites, previous HE, development of 
complications, serum bilirubin, INR, serum creatinine, serum sodium, leukocyte count, 
vasopressin levels, mean arterial pressure and Child-Pugh and MELD scores 
(supplementary table 3). 
 
Finally, a logistic regression model was created to identify the independent predictive 
factors of 3-month mortality. In order to avoid collinearity with Child-Pugh and MELD 
scores, individual variables included in these scores were not included in the model. 
The model showed that plasma copeptin together with MELD score and leukocyte 
count was an independent predictive factor of 3-month mortality [AUROC 0.860; 95% 
CI (0.811–0.909), table 4]. 
 
An internal validation of the prognostic model was performed with the use of the 
bootstrapping technique. Logistic regression model for 3-month mortality was 
internally validated by means of a bootstrap re-estimation of odds ratio and its 
confidence intervals. The model was fitted on 10,000 samples obtained with 
replacement from the study population. Estimations from the original model were 
considered to be validated if they were within the limits of these intervals. 
Bootstrapping for the prognostic model shows the following results (odds ratio and 
95% CI): copeptin 1.654 (1.165–2.457), MELD score 1.179 (1.123–1.265) and leukocyte 
count 2.035 (1.160–4.100). 
 
 
 
External validation 
 
To validate the role of copeptin as an independent predictive factor of mortality, we 
analyzed an independent cohort of patients from different European centers. A 
subgroup of 120 patients was randomly selected from patients included in the 
CANONIC Study.28 Eligibility criteria for patients from the validation series were the 
same as those for the study cohort. Baseline clinical and liver and kidney function tests 
of the validation series are shown in table 5. Overall, median plasma copeptin levels 
were 19 pmol/L (IQR=10–44). A logistic regression model was performed to evaluate 
the best independent predictive factors of 3-month mortality in this series. Results 
were comparable to those obtained in the study population, showing that plasma 
copeptin was an independent predictive factor of 3-month mortality [AUROC 0.827; 
95% CI (0.743–0.910), table 4]. 
 
 
DISCUSSION 
 
The main finding of the current study is that plasma copeptin is an independent 
predictive factor of acute decompensation and mortality in patients with cirrhosis. The 
role of copeptin as prognostic biomarker has been investigated in several acute and 
chronic diseases such as heart failure, chronic respiratory diseases or sepsis;14-20 
however, information in cirrhosis is very limited. To our knowledge, there is only one 
study specifically assessing the role of copeptin in patients with cirrhosis.21 This study 
showed that there was a significant correlation between plasma copeptin levels and 
the severity of liver disease, as defined by Child-Pugh and MELD score, and that 
copeptin was an independent predictive factor of 1-year mortality.21 Nevertheless, the 
study was performed in a low number of patients and did not provide information on 
the relationship between copeptin and systemic hemodynamics and disease 
progression. 
 
Copeptin is the C-terminal fragment of the vasopressin precursor and is secreted from 
the neurohypophysis together with AVP.9,10 Patients with decompensated cirrhosis 
show high levels of AVP in response to hemodynamic stimulus due to the existence of 
effective arterial hypovolemia secondary to splanchnic arterial vasodilation and portal 
hypertension.2,3 Although AVP levels could represent a biomarker of advanced 
cirrhosis, studies on AVP are very limited due to the instability of the molecule making 
its measurement difficult and unsuitable as biomarker. In this context, copeptin as a 
reliable surrogate marker of AVP has interest as potential biomarker of cirrhosis 
progression. 
 
In keeping with the results of previous pathophysiological studies in healthy subjects or 
disorders of AVP secretion11-13, our results indicate that there is a significant 
correlation between plasma AVP and copeptin levels in patients with cirrhosis, a 
condition characterized by extracellular fluid volume expansion and increased AVP 
secretion. Besides correlation with AVP, plasma copeptin levels showed a significant 
correlation with endogenous vasoactive systems, measured by PRA, aldosterone, and 
noradrenaline. Therefore, these results indicate that copeptin clearly reflects the 
progressive circulatory dysfunction that develops in patients with advanced cirrhosis as 
a good surrogate marker of AVP. 
 
Besides its relationship with circulatory dysfunction, our results show that plasma 
copeptin levels progressively increase with the impairment of liver function as 
assessed by MELD score. Moreover, patients with previous history of decompensation 
of cirrhosis had significantly higher copeptin levels compared to patients with 
compensated cirrhosis. Nevertheless, the most novel and main result of our study is 
that copeptin is not only related with the impairment of liver function but also with 
clinical outcomes. Patients developing complications of the disease and those who 
died during follow-up showed higher baseline plasma copeptin levels compared to 
those of patients who did not develop complications and remained compensated. 
Finally, and most interestingly, in the multivariate analysis, plasma copeptin was an 
independent predictive factor of the development of complications of cirrhosis and 3-
months mortality. Moreover, the performance of the predictive model of mortality 
was validated in an independent cohort of patients from other centers. 
 
Assessment of prognosis in patients with cirrhosis has been based on standard liver 
tests.29 Several variables, such as MELD score and serum sodium, have been described 
as prognostic factors in cirrhosis in terms of mortality.30-32 Other non-liver specific 
parameters such as inflammatory biomarkers (i.e., C-reactive protein) or vasoactive 
molecules (i.e., adrenomedullin, cortisol) have also been shown to be related with 
severity of cirrhosis and mortality in some studies.33-35 However, to our knowledge 
there are no studies specifically assessing predictive factors of acute decompensation 
in patients with cirrhosis. Although MELD score is already known as a good and 
accurate variable to assess prognosis, results of the present study show that copeptin 
has some prognostic value independent of MELD score. In view of the results of our 
study, copeptin appears to be a reliable biomarker of disease progression and clinical 
decompensation in patients with cirrhosis. Considering these results we can 
hypothesize that its accuracy in predicting complications and prognosis may be related 
to the capacity of copeptin to reflect circulatory disturbances in patients with 
advanced cirrhosis, which are responsible, at least in part, for development of 
complications of the disease. In this context and considering that copeptin is a stable 
molecule and much easier to measure than AVP, it should be pointed out that 
copeptin is a better biomarker of disease progression and prognosis compared to 
vasopressin. Therefore, we believe that copeptin could be helpful in the assessment of 
prognosis of patients with cirrhosis. Increased plasma copeptin levels indicate that a 
patient is at increased risk of developing complications in the following months. This 
would be important information for clinicians in order to monitor these patients more 
strictly to prevent or early diagnose potential complications. 
 
We also investigated the relationship between copeptin and hyponatremia and kidney 
function. It is well-known that non-osmotic secretion of AVP is the key mechanism of 
hyponatremia in patients with cirrhosis.2,36 Therefore, considering the good correlation 
between copeptin, AVP, and circulatory function it would be expected that plasma 
copeptin levels could also play a role as biomarker of hyponatremia. Our results show 
an inverse and significant correlation between copeptin and serum sodium levels. 
Moreover, patients with hyponatremia showed higher plasma copeptin levels 
compared to those of patients with normal serum sodium. However, plasma copeptin 
levels were not able to identify those patients with increased risk of development of 
hyponatremia during follow-up. Although AVP seems to play a key role, the 
pathophysiology of hyponatremia in cirrhosis is complex and multifactorial. Other 
factors such as glomerular filtration rate and renal prostaglandin E2 production are 
also involved.2 Therefore, the effect of other factors different from AVP in the 
impairment of solute-free water retention in cirrhosis may be the reason to explain the 
lack of accuracy of copeptin in predicting development of hyponatremia. With respect 
to kidney function, our results show that there is a significant correlation between 
copeptin and kidney function, as estimated by serum creatinine levels. Moreover, 
patients who developed kidney failure during follow-up showed significantly higher 
baseline plasma copeptin levels compared to patients who did not develop kidney 
failure. To our knowledge, there is no previously reported information on the 
relationship between copeptin and kidney function. Copeptin is a small molecule with 
a molecular weight of 5 KDa.10 Therefore, as it is filtered by the kidney its levels may be 
influenced by changes in GFR. In this context, it could be hypothesized that high 
plasma copeptin levels in patients with cirrhosis and kidney failure could be explained, 
at least in part, by the reduction in GFR. 
 
Finally, it should be considered that this is a single center study and this could 
represent a limitation in order to extrapolate the results. However, the main results of 
the study have been successfully validated in an independent cohort of patients from 
other centers. There were few missing values in some of the variables of the study, 
which could represent a limitation for the analysis. However, it should be noted that 
missing values for the most important variables was very low so that this may not have 
had an impact on the results. 
 
In conclusion, the results of the present study indicate that copeptin is a novel and 
reliable biomarker of disease progression, clinical decompensation, and prognosis in 
patients with cirrhosis. Results suggest that copeptin reflects the progressive 
impairment of circulatory function that occurs in patients with advanced cirrhosis, as a 
good surrogate marker of AVP. 
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TABLES AND FIGURES 
 
Table 1. Demographic and clinical data and liver and kidney function tests of the 265 
patients included in protocol 2.  
 
Variable 
Age (years)       60±11  (21-85) 
Gender, male       176 (66%)    
Etiology of cirrhosis: 
      Alcohol       114 (43%)   
      Hepatitis C       91 (34%) 
      Other       60 (23%)  
Active alcoholism      77 (29%)   
Previous ascites      189 (71%)    
Previous hepatic encephalopathy    96 (36%)   
Cause of admission  
      Bacterial infections     82 (26%)   
      Ascites       71 (22%)    
      Hepatic encephalopathy     31 (10%)   
      GI bleeding      24 (8%) 
      Kidney failure      15 (5%) 
      Other       42 (13%)    
Shock at admission      24 (8%)    
Serum bilirubin (mg/dL)     5.9±7.7 (0.3-40)  
Serum albumin (g/L)      27±5  (17-44) 
INR        1.7±0.5 (0.9-4.4) 
Child-Pugh score      9±2  (5-14) 
MELD score       17±8  (7-40)  
Serum creatinine (mg/dL)     1.3±0.9 (0.4-9.2)  
Serum sodium (mEq/L)     135±5  (114-148) 
Leukocyte count (109 cells/L)     6.9±5  (0.6-39) 
Mean arterial pressure (mmHg)    84±14   (40-131)  
Copeptin (pmol/L) δ      14 (7-32) 
Vasopressin (ng/L)      2.1 (1.4-2.9) 
 
Data are expressed as mean ± standard deviation and ranges or number and 
percentages, except for copeptin and vasopressin which are expressed as median 
(interquartile range).  
δMedian plasma copeptin levels in a series of 20 healthy volunteers were 8.5 pmol/L 
(IQR 3.9-14.5).  
 
 
 
 
 
 
 
Table 2. Plasma copeptin levels according to development of complications of cirrhosis 
during follow up.  
 
Complications of cirrhosis   Yes   No  p-value 
 
Any complication (n=206)  17 (9-38)    8.6 (6-17)         0.007 
Bacterial infections (n=121)   17 (9-42)  11 (6-21)                 <0.0001  
Hepatic encephalopathy (n=101) 19 (10-40)  11 (6-21)         0.001  
Kidney failure (n=86)    31 (16-52)  10 (6-19)                <0.0001  
Ascites (n=66)    15 (8-30)  12 (7-29)           0.637  
Hyponatremia (n=46)   13 (7-38)  13 (7-26)         0.567  
GI bleeding (n=28)   28 (10-75)  12 (7-27)         <0.0001 
 
 
Plasma copeptin levels are in pmol/L and are presented as median (interquartile 
range).  
Numbers in brackets after each complication represent the number of patients who 
developed each complication during the 3-month follow-up period.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Independent predictive factors of development of complications of cirrhosis 
during follow up. Multivariate analysis.  
 
Variable OR 95% CI p-value 
Copeptin 1.575 1.102-2.252 0.013 
Serum sodium 0.894 0.825-0.970 0.007 
 
AUROC 0.723; 95% CI (0.650-0.796) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Independent predictive factors of 90-day mortality. Multivariate analysis.  
 
Model 1: Study population.  
Variable OR 95%IC p-value 
Copeptin 1.664 1.140-2.429 0.008 
MELD score 1.191 1.123-1.264 <0.0001 
Leukocyte count 1.951 1.095-3.477 0.023 
 
AUROC 0.860; 95% CI (0.811-0.909) 
 
Model 2: Validation series.  
Variable OR 95%IC p-value 
Copeptin 2.03 1.140-3.60 0.016 
MELD score 1.15 1.070-1.230 <0.001 
 
AUROC 0.827; 95% CI (0.743-0.910) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Demographic and baseline liver and kidney function of the 120 patients 
included in the validation series.  
 
Variable 
Age (years)       57±11  (24-84) 
Gender, male       72 (60%)    
Etiology of cirrhosis: 
      Alcohol       57 (51%)    
      Hepatitis C       21 (19%)  
      Other       34 (30%)    
Previous ascites      85 (71%)    
Previous hepatic encephalopathy    48 (40%)    
Shock at admission      2 (2%)    
Serum bilirubin (mg/dL)     7.0±9.5 (0.4-55)  
Serum albumin (g/L)      29±6  (14-44) 
INR        1.7±0.6 (1.0-4.4) 
Child-Pugh score      10±2  (5-15) 
MELD score       20±8  (6-40)  
Serum creatinine (mg/dL)     1.4±1.1 (0.5-6.8)  
Serum sodium (mEq/L)     135±6.2 (115-149) 
Leukocyte count (109 cells/L)     7.2±5.5 (1.3-41) 
Mean arterial pressure (mmHg)    82±14   (47-131)  
Copeptin (pmol/L)       19   (10-44) 
 
Data are expressed as mean ± standard deviation and ranges or number and 
percentages, except for copeptin which is expressed as median (interquartile range).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Plasma copeptin levels according to disease status in patients included in 
protocol 1. (A) Plasma copeptin levels in patients categorized according to 
compensated or decompensated cirrhosis. (B) Plasma copeptin levels in patients 
categorized according to median MELD score of the whole series. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
Figure 2. Kaplan-Meier curves showing probability of survival during the 3-month 
follow-up period in patients included in protocol 2. Categorized according to median 
baseline plasma copeptin levels of the whole series. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary table 1. Demographic and clinical data and liver and kidney function 
tests of patients included in protocol 1.  
 
Variable 
Age (years)       60±11  (43-85) 
Gender, male       36 (64%)    
Etiology of cirrhosis: 
      Alcohol       30 (54%)   
      Hepatitis C       17 (30%)    
      Other       9 (16%)  
Active alcoholism      11 (20%) 
Previous ascites      38 (68%)    
Previous hepatic encephalopathy    16 (29%)   
Serum bilirubin (mg/dL)     3.3±4.9 (0.4-23)  
Serum albumin (g/L)      33±8  (17-45) 
INR        1.4±0.5 (0.9-4.4) 
Child-Pugh score      7±2  (5-14) 
MELD score       11±8  (4-30)  
Serum creatinine (mg/dL)     0.9±0.74 (0.4-2.3)  
Serum sodium (mEq/L)     134±8  (114-145) 
Leukocyte count (109 cells/L)     6.8±4  (1.8-19) 
Mean arterial pressure (mmHg)    85±14   (50-112)  
Vasoactive systems: 
      Copeptin (pmol/L)δ     12 (4.7-26) 
      Vasopressin (ng/L)              1.8 (1.2-2.5) 
      Plasma renin activity (ng/mL*h)*   2.4 (0.5-6.9)  
      Aldosterone (ng/dL)*     47 (10.4-116) 
      Noradrenaline (pg/mL)*     278 (175-501)   
 
 
Data are expressed as mean ± standard deviation and ranges or number and 
percentages, except for vasoactive systems which are expressed as median 
(interquartile range).  
 
* Normal values are: Vasopressin: 1.5-3.3 ng/L; Plasma renin activity: 0.5-2.3 ng/mL*h; 
Aldosterone: <30 ng/dL; Noradrenaline: 136-364 pg/mL. 
δ Median plasma copeptin levels in a series of 20 healthy volunteers were  
8.5 pmol/L (IQR 3.9-14.5). 
Supplementary table 2. Univariate analysis of the development of complications of cirrhosis 
during follow-up. 
 
 Complications 
(n=206) 
No complications 
(n=59) 
p-value 
Age (years) 60±11 60±13 0.900 
Previous ascites 155 (75%) 34 (58%) 0.008 
Previous hepatic 
encephalopathy 
84 (41%) 12 (20%) 0.003 
Previous bacterial infections 23 (11%) 3 (3%) 0.05 
Shock at admission 21 (10%) 3 (5%) 0.177 
Serum bilirubin (mg/dL) 6.3±8.1 4.2±6.1 0.029 
Serum albumin (g/L) 27±5 28±7 0.194 
INR 1.8±0.5 1.6±0.4 0.035 
Serum creatinine (mg/dL) 1.3±1.1 0.9±0.5 <0.0001 
Serum sodium (mEq/L) 134±5 136±5 0.002 
Leukocyte count (109 cells/L) 7.1±4.7 6.2±6.2 0.241 
Mean arterial pressure 
(mmHg) 
83±14 85±12 0.631 
MELD score 18±9 13±7 <0.0001 
Child Pugh score 10±2 8±2 <0.0001 
Vasopressin (ng/L) 2.8±2.9 2.0±1.1 0.030 
Copeptin (pmol/L) 31±42 15±19 <0.0001 
 
Data are expressed as mean ± standard deviation and or number and percentages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary table 3. Univariate analysis of 90-day mortality. 
 
 Alive 
(n=186) 
Dead 
 (n=79) 
p-value 
Age (years) 61±11 59±11 0.418 
Previous ascites 119 (65%) 67 (85%) 0.001 
Previous hepatic 
encephalopathy 
58 (32%) 38 (48%) 0.009 
Previous bacterial infections 16 (9%) 8 (10%) 0.441 
Shock at admission 14 (8%) 10 (12%) 0.146 
Serum bilirubin (mg/dL) 4.0±5.3 10±10 <0.0001 
Serum albumin (g/L) 27±5 28±6 0.386 
INR 1.6±0.5 1.9±0.6 <0.0001 
Serum creatinine (mg/dL) 1.0±0.5 1.8±1.5 <0.0001 
Serum sodium (mEq/L) 135±4.6 133±5.0 0.002 
Leukocyte count (109 cells/L) 5.9±4.3 9.2±5.9 <0.0001 
Mean arterial pressure 
(mmHg) 
85±13 80±15 0.014 
MELD score 16±6 25±7 <0.0001 
Child Pugh score 9±2 11±2 <0.0001 
Vasopressin (ng/L) 2.3±2.7 3.6±2.3 < 0.001 
Copeptin (pmol/L) 20±26 46±55 <0.0001 
Complications during follow-
up 
129 (70%) 77 (98%) <0.0001 
 
Data are expressed as mean ± standard deviation and or number and percentages. 
 
 
